DIQTA 1.0: Drug-Induced QT Prolongation Atlas

LACOSAMIDE

Classification:Ambiguous

Severity Score:1.0

CLINICAL PHARMACOLOGY
Pharmacodynamics
Cardiac electrophysiology
Electrocardiographic effects of VIMPAT were determined in a double-blind, randomized clinical pharmacology trial of 247 healthy subjects. Chronic oral doses of 400 and 800 mg/day were compared with placebo and a positive control (400 mg moxifloxacin). VIMPAT did not prolong QTc interval and did not have a dose-related or clinically important effect on QRS duration. VIMPAT produced a small, dose-related increase in mean PR interval. At steady-state, the time of the maximum observed mean PR interval corresponded with t max. The placebo-subtracted maximum increase in PR interval (at t max) was 7.3 ms for the 400 mg/day group and 11.9 ms for the 800 mg/day group. For patients who participated in the controlled trials, the placebo-subtracted mean maximum increase in PR interval for a 400 mg/day VIMPAT dose was 3.1 ms in patients with partial-onset seizures and 9.4 ms for patients with diabetic neuropathy.

Current Drug

Other Drugs

QT Prolongation

24066

Other ADRs

26955

38354632

Odds Ratio = 1.538

ATC Code(s):

Active Ingredient:LACOSAMIDE

Active Ingredient UNII:563KS2PQY5

Drugbank ID:DB06218

PubChem Compound:219078

CAS Number:175481-36-4

Dosage Form(s):tablet, film coated

Route(s) Of Administrator:oral

Daily Dose:

Chemical Structure:

SMILE Code:
COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1

N/A